Archives
-
Periodontopathogens Redirect Angiotensin I to Ang-(1–7)
2026-10-01
The reference study identifies surface-associated PepO metalloproteases from Porphyromonas gingivalis and Tannerella forsythia as pathogen-derived enzymes that hydrolyze angiotensin I and favor formation of Angiotensin (1-7). By combining biochemical profiling, structural biology, bacterial localization studies, and a Galleria mellonella infection model, the authors connect oral microbial proteolysis with local renin–angiotensin system remodeling while showing that the effect on virulence is species-specific.
-
Hydrocortisone Butyrate: Stability as a Study Variable
2026-10-01
Hydrocortisone butyrate research is more informative when receptor activity is interpreted alongside chemical identity and exposure history. This guide uses PLGA delivery evidence to develop practical assay strategies for dermatitis, epidermal physiology, and cutaneous inflammation models.
-
Sisomicin: From Ribosome Binding to Translation
2026-09-30
Sisomicin is an aminoglycoside antibiotic whose 30S ribosomal activity, isolate-level spectrum, resistance profile, and exposure limits make it valuable for translational infection research. This article connects historical susceptibility evidence with practical assay design, competitive positioning, and clinically relevant decision-making.
-
MCC950 Sodium: NLRP3 Assay Workflow Guide
2026-09-30
MCC950 sodium, also known as CRID3 sodium salt, enables selective interrogation of NLRP3 signaling rather than broad suppression of inflammatory responses. This guide translates endothelial pyroptosis findings into practical macrophage, cytokine, disease-model, and troubleshooting workflows.
-
Integrated Genomics in Pleural Mesothelioma
2026-09-29
The 2021 Scientific Reports study integrated copy-number profiling, sequencing, and transcriptomics to identify immune and signaling vulnerabilities in pleural mesothelioma. Its findings connect recurrent SUFU, interferon, CDKN2A, RB1, and Hippo pathway alterations with survival patterns and ex vivo responses to pathway-directed inhibitors, providing a framework for biomarker-led research.
-
Ivermectin: Mechanism and Research Workflow
2026-09-29
Ivermectin is a broad-spectrum anti-parasitic used in approved treatments for selected parasitic and dermatologic conditions. The A2813 research material supports controlled parasitology experiments, but the cited Gasdermin C pancreatic cancer study does not establish ivermectin as an oncology treatment.
-
Calnexin, CFTR Variants, and Corrector Rescue
2026-09-28
Tedman et al. used deep mutational scanning to show that the ER chaperone calnexin shapes CFTR surface expression and corrector responsiveness in a variant- and domain-dependent manner. The study separates proteostatic rescue from channel function, offering a stronger framework for interpreting genotype-specific responses in cystic fibrosis research.
-
ACT-III: Vernakalant for Rapid AF Conversion
2026-09-28
The ACT-III randomized trial found that intravenous vernakalant converted short-duration atrial fibrillation to sinus rhythm more often than placebo, with a median conversion time of eight minutes among responders. Its design and results support a rapid-conversion role for RSD1235 in selected patients, while the trial’s eligibility criteria and serious adverse event highlight the importance of patient selection and safety assessment.
-
EZ Cap™ Cas9 mRNA (m1Ψ): Editing Workflow
2026-09-27
A practical guide to using Cap1-capped, m1Ψ-modified Cas9 mRNA with guide RNA for mammalian-cell editing studies. Learn how to plan a small delivery pilot, separate product specifications from starting recommendations, and troubleshoot expression, viability, and editing readouts.
-
Protease Inhibitor Cocktail for Mbd5 Workflows
2026-09-26
Protect Mbd5-associated proteins during lysate preparation for co-immunoprecipitation, pull-downs, and immunoblotting without adding EDTA that can disrupt divalent-cation-sensitive assays. This practical guide connects the zebrafish Mbd5 study to sample handling choices—and explains when a protease cocktail alone is not enough.
-
EZ Cap™ Cas9 mRNA (m1Ψ) for Editing Workflows
2026-09-25
Explore how Cap1-capped, m1Ψ-modified Cas9 mRNA can support CRISPR experiments in mammalian cells and mouse zygotes. The workflow combines evidence from a zygote electroporation study with practical handling, delivery optimization, and troubleshooting guidance—while clearly distinguishing published conditions from starting-point recommendations.
-
Necrostatin-1 for RIP1 Kinase Workflows
2026-09-25
Use Necrostatin-1 to test whether RIP1 kinase activity contributes to stimulus-driven cell death, with a reported 30 µM, 24-hour condition as a practical benchmark. The workflow also shows how to investigate necrosis in host–parasite experiments without treating the reference study’s findings as proof of RIP1 involvement.
-
Sodium Overload Disrupts Mitochondrial Energy in NECSO
2026-09-24
Qiao and colleagues identify mitochondrial energy failure as a mechanism linking TRPM4-mediated sodium entry to necrosis in NECSO. Their findings connect increased mitochondrial sodium and reduced mitochondrial calcium with impaired oxidative phosphorylation and TCA-cycle activity, ATP depletion, and eventual failure of ion homeostasis.
-
Hypoxia duration shapes urothelial inflammasome activation
2026-09-24
A rat urothelial cell study found that short enzyme-induced hypoxia stabilized HIF-1α and increased nitric oxide activity without a detectable caspase-1 response, whereas longer exposure increased intracellular caspase-1. Attenuation by glutathione and verapamil supports a ROS/TXNIP-linked inflammatory mechanism, while the in vitro design leaves important questions about pathway specificity and bladder-level transferability.
-
CDK9 inhibitor A3294: Practical Lab Guide
2026-09-23
CDK9 inhibitor A3294 is a selective tool for probing CDK9-dependent transcription elongation and P-TEFb activity, with product-reported biochemical potency and HIV-1 assay findings. Use it for focused CDK9 experiments, not as a broad-spectrum CDK inhibitor or as evidence of general cytotoxic activity.